NCT05781334Completed
Optimizing In-hospital Use of Evidence-based Therapies for Patients With Cardio-Renal-Metabolic Disease
Identifying Barriers to and optiMizing In-hosPitaL usE of Evidenced-based Medical thErapies for patieNTs With Cardio-Renal-Metabolic Disease
Source: ClinicalTrials.gov · Last updated 20 Sept 2024
Brief summary (registry, in English)
This study will be a prospective randomized implementation trial for patients hospitalized with heart failure, chronic kidney disease, and/or type 2 diabetes mellitus within Duke University Medical Center. The primary hypothesis is that a virtual quality improvement-based consult intervention will improve the rate of in-hospital evidence-based cardio-renal-metabolic medication use, particularly SGLT2 inhibitor therapy. Approximately 200 patients meeting eligibility criteria will be included in the study. Patients will be assigned into study groups, as defined by randomization of their treating clinician team to receiving the virtual consult versus not.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 202 (actual)
- First submitted
- 16 Feb 2023
- Start date
- 9 Jun 2023
- Primary completion date
- 31 Aug 2024
- Lead sponsor
- Duke University
- NCT number
- NCT05781334
What you commit to
- Study type: Interventional
- Participants enrolled: 202
- From 9 Jun 2023 to the primary completion date, 31 Aug 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Implanted left ventricular assist device or implant anticipated within 3 months.
Other illness
- History of heart transplant or actively listed for heart transplant
- Active cancer (except localized prostate, breast, or non-melanoma skin cancers)
Lab values
- End-stage stage renal disease on dialysis or eGFR \<20 mL/kg/1.73m2.
Other
- Pre-menopausal woman who are either breast-feeding or pregnant
- Enrolled in or planning to enroll in hospice care.
Who the study is looking for
- 1\. Hospitalized adults age ≥ 18 years with ≥1 of the following diagnoses, as defined by the medical record:
- HF (any ejection fraction)
- CKD with estimated GFR ≥ 20 mL/min/1.73m2 \*
- T2DM (by clinical history or hemoglobin A1c)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Duke University Medical Center Coordinator of this site? Confirm its status | Durham | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.